Predicting Outcome and Disease Course in acquired demyelinating syndromes in childhood

• Conditions: Multiple Sclerosis; 10012303

• Registration Number: NL-OMON55633
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 1200

Inclusion Criteria

Patients
1. Age under 18 years
2. Auto-immune mediated, demyelinating disorder of the CNS
3. No other suspected disease causing demyelination in the CNS
4. Written informed consent is obtained of parents or caregivers. In case the
patient is 12 years of age or older, the patient needs to provide written
informed consent as well. , Healthy controls
1. Age under 18 years
2. No known systemic auto-immune disease
3. Full siblings (same father and same mother) of the patient are eligible and
not blood-related children sharing similar environments (school, neighbourhood
etc).
4. Written informed consent is obtained , Other neurological diseases (OND):
Patients will be included at the outpatient clinics of pediatric neurologists
at Erasmus MC-Sophia.
1. Age under 18 years
2. No systemic auto-immune disease that might cause inflammatory disease in the
CNS
3. Written informed consent is obtained of parents or caregivers. In case the
child is 12 years of age or older, the child needs to provide written informed
consent as well.

Exclusion Criteria

1) Age of onset above 18 years
2) Inflammation in the CNS by other causes than ADS (for example systemic lupus
erythematosus, Sj*gren syndrome, sarcoidosis,).
3) If written informed consent is not obtained.
4) Withdrawal from study by patient and/or parents.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Identifying prognostic factors for disease course and severity<br /><br>- Identification of specific ADS subgroups<br /><br>- Role of environmental and genetic factors in MS and other ADS<br /><br>- Estimating incidence and prevalence of ADS subtypes in the Netherlands.<br /><br>- Accurate and suitable parameters expressing disease severity for pediatric<br /><br>ADS</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>